Etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue as re-treatment for unfavorable non-Hodgkin's lymphoma.
Fifteen patients with unfavorable, non-Hodgkin's lymphoma refractory to front-line chemotherapy were treated with etoposide, carmustine, bleomycin, and methotrexate with leucovorin rescue. Four patients achieved complete response and two achieved partial response. The durations of the complete responses were 4, 12, 24, and 32 months, respectively. Three of the four complete responses occurred in five patients who failed to respond to initial combination chemotherapy. The major toxic effects were severe myelosuppression in eight of 52 courses and pulmonary fibrosis in two patients. This regimen is useful in inducing durable remissions in patients with refractory, unfavorable, non-Hodgkin's lymphomas.
Helms
S R
SR
Oblon
D J
DJ
Braylan
R C
RC
Weiner
R S
RS
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D004351:Drug Resistance; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008171:Lung Diseases / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D012008:Recurrence
D001761:Bleomycin; D005047:Etoposide; D002955:Leucovorin; D002330:Carmustine; D008727:Methotrexate